# Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial

> **NCT00629213** · PHASE3 · COMPLETED · sponsor: **GWT-TUD GmbH** · enrollment: 1429 (—)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** acarbose
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00629213
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1429 (—)
- **Last updated:** 2008-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629213, "Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00629213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*